ESSA Pharma Inc. (EPI)

ESSA Pharma Inc. (EPI $8.20)
- $8.20 Cap: $363M
- View EPI Profile
- View Questions on EPI

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

ESSA Pharma Inc. (EPI $8.20)
- $8.20 Cap: $363M
- View EPI Profile
- View Questions on EPI
IDEAYA Biosciences Inc. (IDYA $21.43)
- $21.43 Cap: $1.87B
- View IDYA Profile
- View Questions on IDYA
Certara Inc. (CERT $10.41)
- $10.41 Cap: $1.80B
- View CERT Profile
- View Questions on CERT

Q: ESSA Pharma is just one example of an exciting pharma in a topically interesting (prostate cancer, aging population…) area but with impenetrable valuation characteristics. Can you say whether this stock’s prospects are worth its price? Are there other early-stage pharmas you like?

Read Answer Asked by David on January 16, 2024